473829-50-4

Basic information

• Product Name: Bicyclo[3.1.0]hexane-2-acetic acid, 2-(aminomethyl)-6,6-dimethyl-, (1R,2S,5S)- (9CI)
• Synonyms: Bicyclo[3.1.0]hexane-2-acetic acid, 2-(aminomethyl)-6,6-dimethyl-, (1R,2S,5S)- (9CI)
• CAS NO: 473829-50-4
• Molecular Formula: C11H19NO2
• Molecular Weight: 197.27406
• Product Categories: CYCLOPENTANE
• Mol File: 473829-50-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Bicyclo[3.1.0]hexane-2-acetic acid, 2-(aminomethyl)-6,6-dimethyl-, (1R,2S,5S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Bicyclo[3.1.0]hexane-2-acetic acid, 2-(aminomethyl)-6,6-dimethyl-, (1R,2S,5S)- (9CI)(473829-50-4)
• EPA Substance Registry System: Bicyclo[3.1.0]hexane-2-acetic acid, 2-(aminomethyl)-6,6-dimethyl-, (1R,2S,5S)- (9CI)(473829-50-4)

Safety Data

• Hazardous Substances Data: 473829-50-4(Hazardous Substances Data)

Relevant articles and documents

Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity

The present invention provides an extended release oral dosage form of prodrugs of fused GABA analogs of reduced toxicity. The dosage forms are particularly useful in administering those fused GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which fused GABA analog are known to be therapeutically effective.

Fused bicyclic or tricyclic amino acids

The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.